Human phospho-Lck (Y394) Antibody (755103)
R&D Systems | Catalog # MAB7500
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Accession # P06239
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human phospho-Lck (Y394) Antibody (755103)
Detection of Human Phospho-Lck (Y394) by Western Blot.
Western blot shows lysates of Jurkat human acute T cell leukemia cell line and Ramos human Burkitt's lymphoma cell line untreated (-) or treated (+) with 1 mM Pervanadate (PV) for 5 minutes. PVDF membrane was probed with 0.1 µg/mL of Mouse Anti-Human Phospho-Lck (Y394) Monoclonal Antibody (Catalog # MAB7500) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for Phospho-Lck (Y394) at approximately 56 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Phospho‑Lck (Y394) in Jurkat Human Cell Line.
Lck phosphorylated at Y394 was detected in immersion fixed Jurkat human acute T cell leukemia cells treated with (upper panel) or without (lower panel) Pervanadate using Mouse Anti-Human Phospho-Lck (Y394) Monoclonal Antibody (Catalog # MAB7500) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.Detection of f2taqonjiwgimc7btuo5.jpg by Western Blot
Pretreatment with LCK inhibitor followed by LCKi-cisplatin treatment attenuates tumor burden, and treated tumors indicate decreased P-LCK. NSG mice were injected with CP70-luciferase transfected cells followed by pretreatment with LCKi (6 mice) or vehicle (24 mice) for 14 days. LCKi mice were then co-treated with LCKi and cisplatin, and vehicle mice were randomized to further treatment with vehicle, cisplatin, saracatinib, or combination (6 mice per arm) (a). IVIS imaging was obtained on a weekly basis to assess tumor growth (b). IVIS luminescence was corrected to baseline for each arm and assessed over time (c) and at the experimental endpoint (d). Tumors from NSG mice were extracted, and protein lysates were prepared and immunoblotted for protein expression of P-LCK (Y394) and T-LCK. Fold changes of protein expression are shown in the figure, with values normalized to vehicle control. GAPDH was used as a loading control (e). Two tumors per condition were probed, with at least three technical replicates performed. Mouse body weight at day 7, 21, and 28 were obtained for each arm, with weights shown as fold change from baseline (f) Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33888137), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of fmtslydn7u79t2logeav.jpg by Western Blot
Loss of phosphorylation at S224 and S241 prevents LAT tyrosine phosphorylation, binding to the signalosome, and cytokine production(A) JLAT transductants with DNA-PKcs phosphorylation sites 224 or 241 mutated, stimulated with 5 μg/mL alpha CD3/CD28 for 24 h, are unable to produce IL-2, as assessed by ELISA. Data are represented as mean ± SEM.(B) Western blot analysis of ZAP70 tyrosine phosphorylation events on LAT (Y132, 171, and 191) in resting or 2-min alpha CD3/CD28 (5 μg/mL) TCR-stimulated JLAT transductants. Following 2-min alpha CD3/CD28 stimulation, tyrosine’s 132, 171, and 191 are phosphorylated in WT and S224A JLAT transductants but not in S241A and S2A JLAT transductants.(C) ImageJ quantification of band intensity shows that WT and S224A LAT have tyrosine phosphorylation (132, 171, and 191) 9-fold higher than the S241 and S2A transductants, with one dot representing one experiment. Data are represented as mean ± SEM.(D) ZAP70 tyrosine phosphorylation of residues 132, 171, and 191 on LAT is blocked with pan-PI3K inhibitor LY294002 (20 μM) but not with selective PI3K inhibitors in WT LAT transduced JLAT T cells.(E) ImageJ quantification of band intensity shows tyrosine phosphorylation (132, 171, and 191) 2.5-fold lower in WT LAT-transduced JLAT T cells treated with LY294002 compared to other inhibitors tested, with one dot representing one experiment. Data are represented as mean ± SEM.Representative blots from n = 3 independent experiments. One-factor ANOVA plus Tukey’s multiple comparisons to determine statistical significance ( alpha = 0.05, *p < 0.05, **p < 0.01, ***p < 0.0005, and ****p < 0.0001). Image collected and cropped by CiteAb from the following open publication (https://linkinghub.elsevier.com/retrieve/pii/S2211124725015682), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human phospho-Lck (Y394) Antibody (755103)
Immunocytochemistry
Sample: Immersion fixed Jurkat human acute T cell leukemia cell line treated with Pervanadate
Western Blot
Sample: Jurkat human acute T cell leukemia cell line and Ramos human Burkitt's lymphoma cell line treated with Pervanadate
Formulation, Preparation, and Storage
Purification
Reconstitution
Sterile PBS to a final concentration of 0.5 mg/mL. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: Lck
Long Name
Alternate Names
Gene Symbol
UniProt
Additional Lck Products
Product Documents for Human phospho-Lck (Y394) Antibody (755103)
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Human phospho-Lck (Y394) Antibody (755103)
For research use only
Related Research Areas
Citations for Human phospho-Lck (Y394) Antibody (755103)
Customer Reviews for Human phospho-Lck (Y394) Antibody (755103)
There are currently no reviews for this product. Be the first to review Human phospho-Lck (Y394) Antibody (755103) and earn rewards!
Have you used Human phospho-Lck (Y394) Antibody (755103)?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 for a review with an image
$10/€7/£6/$10CAN/¥1110 for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- ClariTSA™ Fluorophore Kits
- Detection & Visualization of Antibody Binding
- ICC Cell Smear Protocol for Suspension Cells
- ICC Immunocytochemistry Protocol Videos
- ICC for Adherent Cells
- Immunocytochemistry (ICC) Protocol
- Immunocytochemistry Troubleshooting
- Immunofluorescence of Organoids Embedded in Cultrex Basement Membrane Extract
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Fluorescent ICC Staining of Cell Smears - Graphic
- Protocol for the Fluorescent ICC Staining of Cultured Cells on Coverslips - Graphic
- Protocol for the Preparation and Fluorescent ICC Staining of Cells on Coverslips
- Protocol for the Preparation and Fluorescent ICC Staining of Non-adherent Cells
- Protocol for the Preparation and Fluorescent ICC Staining of Stem Cells on Coverslips
- Protocol for the Preparation of a Cell Smear for Non-adherent Cell ICC - Graphic
- R&D Systems Quality Control Western Blot Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars